Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Eric P. Grewal, et al. on LinkedIn:
“CAR T Cell Therapy & Gliomas: The Road Ahead.
CAR T cell therapy has transformed care for blood cancers—but bringing that success to malignant gliomas like GBM and DMG remains a major challenge.
Over the past decade, clinical trials targeting glioma-associated antigens such as:
IL-13Rα2, HER2, EGFR/EGFRvIII, EphA2, GD2, and B7-H3.
…have shown proof-of-concept, but hurdles like antigen escape and short-lived T cells remain.
What’s next?
- Multi-antigen targeting.
- Novel delivery routes.
- Alternative cell sources.
These innovative approaches are pushing the boundaries of what’s possible in brain tumor immunotherapy. Continued evolution is key to unlocking durable responses and expanding the CAR T frontier.”
Clinical progress in the development of CAR T cells to treat malignant glioma.
Authors: Eric P. Grewal, et al.
